A Phase 1/2 interventional study of GLY-230 and Placebo in Diabetic Nephropathy, sponsored by Glycadia. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-02-10.
Sponsored by Glycadia · Phase 1/2, Interventional, and Treatment
A dose-ranging study evaluating safety, metabolism and therapeutic dosing of three multiple dose levels of GLY-230 in healthy and diabetic subjects
534 studies on the registry are indexed under Diabetic Nephropathies; 107 are open to participants now.
This study's enrollment of 42 is below the median of 80 across 377 interventional studies indexed under Diabetic Nephropathies.
Browse Diabetic Nephropathies studies →Glycadia is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: GLY-230
Drug: GLY-230
Drug: GLY-230
Other: Placebo
125, 250 0r 375 mg bid for 14 days
No drug administered
glycated albumimin concentration
Time frame: three weeks
urine albumin
Time frame: three weeks
No study locations are listed for this record.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glycadia